168 related articles for article (PubMed ID: 35788405)
61. Could the chylomicron marker apoB48 be of value in the diagnosis of chylous effusions?
Lefrère B; Sakka M; Fourati S; Levasseur A; Curis E; Cherfils C; Grès P; Guilbert Z; Lacorte JM; Chenevière C; Bittar R; Bonnefont-Rousselot D
Clin Chim Acta; 2023 Jan; 539():184-190. PubMed ID: 36463939
[TBL] [Abstract][Full Text] [Related]
62. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
63. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Hegde A; Andreev-Drakhlin AY; Roszik J; Huang L; Liu S; Hess K; Cabanillas M; Hu MI; Busaidy NL; Sherman SI; Dadu R; Grubbs EG; Ali SM; Lee J; Elamin YY; Simon GR; Blumenschein GR; Papadimitrakopoulou VA; Hong D; Meric-Bernstam F; Heymach J; Subbiah V
ESMO Open; 2020 Oct; 5(5):e000799. PubMed ID: 33097651
[TBL] [Abstract][Full Text] [Related]
64. Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea.
Baek HS; Ha J; Ha S; Bae JS; Jung CK; Lim DJ
Curr Oncol; 2023 Mar; 30(3):3020-3031. PubMed ID: 36975442
[TBL] [Abstract][Full Text] [Related]
65. Unusual Presentation of Bilateral Chylothorax and Chylous Ascites with Pancreatic Adenocarcinoma: A Case Report.
Fangsaard P; Puriwekin J; Phattraprayoon N; Ungtrakul T
Case Rep Oncol; 2022; 15(2):611-616. PubMed ID: 35949900
[TBL] [Abstract][Full Text] [Related]
66. Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
[TBL] [Abstract][Full Text] [Related]
67. Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Drilon A; Lin JJ; Filleron T; Ni A; Milia J; Bergagnini I; Hatzoglou V; Velcheti V; Offin M; Li B; Carbone DP; Besse B; Mok T; Awad MM; Wolf J; Owen D; Camidge DR; Riely GJ; Peled N; Kris MG; Mazieres J; Gainor JF; Gautschi O
J Thorac Oncol; 2018 Oct; 13(10):1595-1601. PubMed ID: 30017832
[TBL] [Abstract][Full Text] [Related]
68. Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Chylothorax and Chylous Ascites in Cirrhosis: A Case Report and Systematic Review of the Literature.
Tsauo J; Shin JH; Han K; Yoon HK; Ko GY; Ko HK; Gwon DI
J Vasc Interv Radiol; 2016 Jan; 27(1):112-6. PubMed ID: 26723922
[TBL] [Abstract][Full Text] [Related]
69. Recurrent chylous effusions and venous thrombosis: Uncommon presentation of a common condition.
Bhatt M; George N; Soneja M; Kumar P; Vyas S; Biswas A
Intractable Rare Dis Res; 2018 Aug; 7(3):200-203. PubMed ID: 30181942
[TBL] [Abstract][Full Text] [Related]
70. RET kinase inhibitors for
Vodopivec DM; Hu MI
Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
[TBL] [Abstract][Full Text] [Related]
71. Chylous ascites and chylothorax due to constrictive pericarditis in a patient undergoing haemodialysis.
Riza Altiparmak M; Avsar S; Yanik S
Neth J Med; 2004 Feb; 62(2):59-61. PubMed ID: 15127833
[TBL] [Abstract][Full Text] [Related]
72. Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.
Murciano-Goroff YR; Falcon CJ; Lin ST; Chacko C; Grimaldi G; Liu D; Wilhelm C; Iasonos A; Drilon A
J Thorac Oncol; 2023 May; 18(5):620-627. PubMed ID: 36657661
[TBL] [Abstract][Full Text] [Related]
73. Chylothorax: the result of previous radiation therapy?
Promisloff RA; Hogue DJ
J Am Osteopath Assoc; 1997 Mar; 97(3):164-6. PubMed ID: 9107128
[TBL] [Abstract][Full Text] [Related]
74. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
75. Chylous ascites and chylothorax.
GRIFFITH RL
Northwest Med; 1948 Nov; 47(11):800-3. PubMed ID: 18892639
[No Abstract] [Full Text] [Related]
76. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
Le D; Konda B
Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
[TBL] [Abstract][Full Text] [Related]
77. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
Hu X; Liu X; Khatri U; Wu J
Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
[TBL] [Abstract][Full Text] [Related]
78. Transjugular intrahepatic portosystemic shunt for treatment of cirrhosis-related chylothorax and chylous ascites: single-institution retrospective experience.
Kikolski SG; Aryafar H; Rose SC; Roberts AC; Kinney TB
Cardiovasc Intervent Radiol; 2013 Aug; 36(4):992-7. PubMed ID: 23207657
[TBL] [Abstract][Full Text] [Related]
79. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Şentürk R; Wang Y; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jun; 1147():122131. PubMed ID: 32416592
[TBL] [Abstract][Full Text] [Related]
80. Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report.
Gazeu A; Aubert M; Pissaloux D; Lantuejoul S; Pérol M; Ikhlef N; Bouhamama A; Franceschi T; Swalduz A
Clin Lung Cancer; 2023 Jan; 24(1):72-75. PubMed ID: 36437214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
